Cipla is the first company to file for the 10mg strength, it added. The product is a generic version of AstraZeneca Pharmaceutical#39;s Nexium. It is indicated for the treatment of gastroesophageal reflux disease, risk reduction of NSAID-associated gastric ulcer, among others, Cipla said.Cipla gets USFDA nod for generic acid reflux drug
Cipla is the first company to file for the 10mg strength, it added. The product is a generic version of AstraZeneca Pharmaceutical#39;s Nexium. It is indicated for the treatment of gastroesophageal reflux disease, risk reduction of NSAID-associated gastric ulcer, among others, Cipla said.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The bank plans to raise up to Rs 500 crore by issue of equity shares to qualified institutional buyers through qualified institutional plac...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment